Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.60 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | OXTR | P30559 | 1/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307308 | 0.88 | DNM1 (0.73) | DNM1 | |
| SCHEMBL4896218 | 0.88 | DNM1 (0.73) | DNM1 | |
| SCHEMBL29448098 | 0.85 | DNM1 (0.56) | LMNADNM1OXTRAVPR1AHTT | |
| SCHEMBL28401064 | 0.85 | DNM1 (0.56) | LMNADNM1OXTRAVPR1AHTT | |
| SCHEMBL411077 | 0.85 | DNM1 (0.66) | LMNAALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL28590221 | 0.82 | ALDH1A1 (0.58) | LMNAALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL28582034 | 0.81 | LMNA (0.76) | LMNAALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL21093338 | 0.80 | ALDH1A1 (0.56) | LMNAALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL28604202 | 0.80 | ALDH1A1 (0.56) | LMNAALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL28583936 | 0.80 | ALDH1A1 (0.56) | LMNAALDH1A1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | LMNA 2506/4885ALDH1A1 2240/4885MAPT 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.